Bevacizumab and Heart Failure Risk in Patients With Breast Cancer: A Thorn in the Side?

Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC).

(2017) A. Brufsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab

(2011) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

(2010) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Heart Disease and Stroke Statistics—2010 Update

(2009) et al.   CIRCULATION

Effects of Food on Bioavailability of Lapatinib: Useful Data, Wrong Conclusion

(2009) Ian F. Tannock   JOURNAL OF CLINICAL ONCOLOGY

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

(2009) Sharon Ann Hunt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition

(2008) Faiez Zannad et al.   EUROPEAN HEART JOURNAL

A Dramatic Story of Hope and Reality

(2007) Edward A. Stadtmauer   JOURNAL OF CLINICAL ONCOLOGY